Answers are grounded in this paper and cite their sources.
INTRODUCTION: While advances in target-based drug discovery (TBDD) have enabled rapid therapeutic candidate identification, these approaches may be less suited to fully address complex, systemic conditions such as radiation injury. Many drugs have been repurposed for radiation injury treatment, with their indications approved by the United States Food and Drug Administration (US FDA). The use of phenotype-based drug discovery (PBDD), as observed with repurposed approved drugs, provides an opportunity to identify and develop radiation countermeasures based on pharmacological ability and to address the systemic nature of the injury. AREAS COVERED: The authors discuss recent and specific examples of advances in PBDD for radiation countermeasures. Approved and investigational drugs are discussed, along with the benefits, limitations, and lessons learned from this approach. Relevant literature published through September 2026 was collected using PubMed. EXPERT OPINION: Several radiomitigators and radioprotectors are being developed using the PBDD approach. Combining PBDD and TBDD may help characterize drug mechanisms, but further development also requires formulation and dosing optimization, and efficacy evaluation appropriate to the intended indication. Drug combinations should be assessed for additional benefit and toxicity. These efforts may help advance promising candidates toward treatments for specific manifestations of radiation injury.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: